Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 82,827 shares, an increase of 1,724.4% from the June 15th total of 4,540 shares. Based on an average daily trading volume, of 262,246 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.8% of the shares of the stock are short sold.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Price Performance

Sonoma Pharmaceuticals stock remained flat at $1.26 during mid-day trading on Friday. 101,758 shares of the company were exchanged, compared to its average volume of 173,805. The firm’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $2.22. The stock has a market cap of $6.04 million, a P/E ratio of -0.67 and a beta of 1.27. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The business had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sonoma Pharmaceuticals presently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.